Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 3, 2006, Pages 275-282

  Yukawa, E ^a   Mamiya, K ^b  

^a DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^b Kashii Sanatorium   (Japan)

Author keywords

CYP2C19; Genetic polymorphism; Non linear Mixed Effects Modelling; Pharmacokinetics; Phenobarbital; Phenytoin

Indexed keywords

CYTOCHROME P450 2C19; PHENOBARBITAL; PHENYTOIN;

ADULT; ARTICLE; ASIAN; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; EPILEPSY; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MICHAELIS CONSTANT; STATISTICAL MODEL;

ADULT; ALGORITHMS; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; DNA; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MODELS, STATISTICAL; NONLINEAR DYNAMICS; PHENOBARBITAL; PHENYTOIN; POLYMORPHISM, GENETIC; POPULATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33745063964     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00712.x     Document Type: Article

References (27)

1. Yukawa E 1996 Optimisation of antiepileptic drug therapy: the importance of serum drug concentration monitoring. Clinical Pharmacokinetics, 31, 120 130.
2. Richen A 1979 Clinical pharmacokinetics of phenytoin. Clinical Pharmacokinetics, 4, 153 169.
3. Veronese ME Mackenzie PI Doecke CJ McManus ME Miners JO Birket DJ 1991 Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochemical and Biophysical Research Communications, 175, 1112 1118.
4. Levy RH Bajpai M 1995 Phenytoin. In : Levy RH Mattson RH Meldrum BS, eds. Interactions with other drugs: mechanistic aspects Antiepileptic drugs, 4th edn. New York : Raven Press, 329 338.
5. Riva R Albani F Contin M Baruzzi A. 1996 Pharmacokinetic interactions between antiepileptic drugs - clinical considerations. Clinical Pharmacokinetics, 31, 470 493.
6. Anderson GD. 1998 A mechanistic approach to antiepileptic drug interactions. The Annals of Pharmacotherapy, 32, 554 563.
7. Reidenberg P Glue P Banfield CR et al. 1995 Effects of felbamate on the pharmacokinetics of phenobarbital. Clinical Pharmacology and Therapeutics, 58, 278 287.
8. de Morais SMF Wilkinson GR Blaisdell J Nakamura K Meyer UA Goldstein JA 1994 The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. Journal of Biological Chemistry, 269, 15419 15422.
9. de Morais SMF Wilkinson GR Blaisdell J Meyer UA Nakamura K Goldstein JA. 1994 Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Molecular Pharmacology, 46, 594 598.
10. Kubota T Chiba K Ishizaki T. 1996 Genotyping of S-mephenytoin 4′-hydrovylation in an extended Japanese population. Clinical Pharmacology and Therapeutics, 60, 661 666.
11. Kimura M Ieiri I Mamiya K Urae A Higuchi S 1998 Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP2C9, in a Japanese population. Therapeutic Drug Monitoring, 20, 243 247.
12. Wang S-L Huang J-D Lai M-D Tsai J-J 1995 Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics, 5, 37 42.
13. Beal SL Sheiner LB. (Eds) 1992 NONMEM users guides. University of California at San Francisco, San Francisco : NONMEM Project Group.
14. Yukawa E Higuchi S Aoyama T 1990 Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update. Chemical & Pharmaceutical Bulletin, 38, 1973 1976.
15. Yukawa E Higuchi S Aoyama T. 1992 Phenobarbitone population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. Journal of Pharmacy and Pharmacology, 44, 755 760.
16. Nation RL Evans AM Milne RW. 1990 Pharmacokinetic drug interactions with phenytoin (Part I). Clinical Pharmacokinetics, 18, 37 60.
17. Nation RL Evans AM Milne RW. 1990 Pharmacokinetic drug interactions with phenytoin (Part II). Clinical Pharmacokinetics, 18, 131 150.
18. Bajpai M Roskos LK Shen DD Levy RH. 1996 Roles of cytochrome P4502C9 and P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metabolism and Disposition, 24, 1401 1403.
19. Kutt H Harden CL 1999 Phenytoin and Congeners. In : Eadie MJ Vajda FJE eds Antiepileptic drugs pharmacology and therapeutics. Berlin Heidelberg : Springer-Verlag, 229 265.
20. Odani A Hashimoto Y Otsuki Y Uwai Y Hattori H Furusho K Inui K 1997 Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clinical Pharmacology and Therapeutics, 62, 287 292.
21. Mamiya K Ieiri I Shimamoto J et al. 1998 The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia, 39, 1317 1323.
22. Mamiya K Hadama A Yukawa E et al. 2000 CYP2C19 polymorphism effect on phenobarbitone pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. European Journal of Clinical Pharmacology, 55, 821 825.
23. Kutt H 1995 Phenobarbital: interaction with other drugs. In : Levy RH Mattson RH Meldrum BS eds Antiepileptic drugs, 4th edn. New York : Raven Press, 389 399.
24. Kapetanovic IM Kupferberg HJ Poter RJ Theodore W Schulman E Penry JK 1981 Mechanism of valproate-phenobarbital interaction in epileptic patients. Clinical Pharmacology and Therapeutics, 29, 480 486.
25. Bernus I Dickinson RG Hooper WD Eadie MJ 1994 Inhibition of phenobarbital N-glucosidation by valproate. European Journal of Clinical Pharmacology, 38, 411 416.
26. Patel IH Levy RH Culter RE 1980 Phenobarbital-valproic acid interaction in normal man. Clinical Pharmacology and Therapeutics, 27, 515 521.
27. Gidal BE Zupanc ML 1994 Potential pharmacokinetic interaction between felbamate and phenobarbital. The Annals of Pharmacotherapy, 28, 455 458.